Amylyx gets first approval for ALS drug from Canada

Health Canada's approval comes ahead of a decision by the U.S. Food and Drug Administration, Canada has approved Amylyx Pharmaceuticals' treatment for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, the drugmaker said on Monday, the first such approval for the oral drug. The decision came with certain conditions, including the release of data from its global late-stage study of about 600 patients, which is expected in 2024, as well as additional studies The approval for the drug, which will be sold in Canada under the brand Albrioza, is based on a mid-stage study in 137 patients and a long-term follow-up phase, which showed it slowed a decline in physical functioning among patients. ALS, whose cause is largely unknown, causes nerve cells in the brain and spinal cord to break down, affecting physical function and resulting in severe disability and death. About 3,000 Canadians are currently living with ALS, with the average life expectancy from the symptom onset being two to five years, according to the company. Health Canada's approval comes ahead of a decision by the U.S. Food and Drug Administration, which is expected by June 29. A panel of outside advisers to the U.S. regulator had in March voted 6-4 against approving the drug for ALS, AMX0035, saying the clinical study data failed to establish it was effective against the disease. Commonly known as Lou Gehrig's disease, ALS entered the spotlight in 2014 due to the "Ice Bucket Challenge", which involved people filming themselves pouring ice-cold water over their heads to raise awareness

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!